Trial · NCT01813136
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to treatment failure (TTF) | up to 36 months | TTF is the time to permanent treatment discontinuation due to any cause after randomization in each arm |
| Secondary | Objective Response Rate (ORR) | 6 months after inclusion | Proportion of patients with a best overall response of Complete Response (CR) or a Partial Response (PR) at the end of the first 6 cycles, according to RECIST criteria 1.1 |
| Secondary | Disease Control Rate (DCR) | 6 months after inclusion | Proportion of patients with a best overall response of Complete Response, Partial Response or Stable Disease at the end of the first 6 cycles, according to RECIST criteria 1.1 |
| Secondary | Progression-Free Survival (PFS) | up to 36 months | Time from date of randomization to the date of event defined as the first documented progression under treatment or death due to any cause. |
| Secondary | Best response rate | up to 36 months | Best response observed from date of randomization |
| Secondary | Duration of response | up to 36 months | Time from the first documented response (CR or PR) to the first documented disease progression or death due to any cause, applies only to patients whose best overall response is CR or PR |
| Secondary | Overall Survival (OS) | up to 36 months | Time from date of randomization to the date of death due to any cause |
| Secondary | Objective Response Rate (ORR) | 6 months after randomization | Proportion of patients with a CR or a PR after 6 cycles from randomization. |
| Secondary | Disease Control Rate (SDR) | 6 months after randomization | The proportion of patients with a SD, PR or CR after 6 cycles from randomization. |
| Secondary | Safety profile of pazopanib | up to 36 months | Adverse events (AE) experienced throughout the study and assessed according the NCI-CTC AE version 4.0. |
| Secondary | Quality of Life (QoL) | At inclusion, randomization and at the end of pazopanib treatment | The score obtained at the EORTC Quality of Life Questionnaire C30 |
| Other | Identification of prognostic biomarkers of clinical outcome. | At inclusion, 1 month and 6 months of treatment (before randomisation) | To study the correlation between clinical response and biomarkers (serum and tissue). |
| Other | Tissue expression of Raf-1 kinase inhibitory protein, PAX8, BRAF, Pi3KCA and Ras. | At inclusion | To perform gene expression profiling and to identify potential candidate genes. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01813136/registered